PMID- 32224502
OWN - NLM
STAT- MEDLINE
DCOM- 20201103
LR  - 20201103
IS  - 2161-5853 (Electronic)
IS  - 2161-5861 (Print)
IS  - 2161-5853 (Linking)
VI  - 27
IP  - 4
DP  - 2020 Jan
TI  - Immune reconstruction inflammatory syndrome in HIV infection: beyond what meets 
      the eye.
PG  - 106-111
AB  - A high proportion of individuals with HIV infection currently are diagnosed at an 
      advanced stage of disease (late presenters), increasing their risk for immune 
      reconstitution inflammatory syndrome (IRIS). IRIS typically occurs within 6 
      months of initiation of antiretroviral therapy (ART) in patients with low CD4+ 
      cell counts and can occur before any marked elevation in CD4+ count is achieved 
      on ART. In addition to low CD4+ count at ART initiation, 2 other major clinical 
      predictors of IRIS are preexisting opportunistic infection (including subclinical 
      infection) and shorter treatment period for opportunistic infection prior to 
      starting ART. Mycobacterial infection-associated IRIS, including tuberculosis 
      (TB)-associated IRIS, and cryptococcal infection-associated IRIS are the most 
      common forms of the syndrome. Corticosteroid prophylaxis and early treatment can 
      be effective in reducing incidence of TB-IRIS and severity of symptoms in select 
      patients. Sterilization of the cerebrospinal fluid should be achieved prior to 
      starting ART in patients with TB meningitis and cryptococcal meningitis. This 
      article summarizes a presentation by Irini Sereti, MD, MHS, at the International 
      Antiviral Society-USA (IAS-USA) continuing education program held in Washington, 
      DC, in April 2019.
FAU - Sereti, Irini
AU  - Sereti I
AD  - National Institute of Allergy and Infectious Disease at the National Institutes 
      of Health, Bethesda, MD, USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Top Antivir Med
JT  - Topics in antiviral medicine
JID - 101560274
RN  - 0 (Anti-Retroviral Agents)
SB  - IM
MH  - AIDS-Related Opportunistic Infections/drug therapy
MH  - Anti-Retroviral Agents/*adverse effects/agonists/immunology/*therapeutic use
MH  - CD4 Lymphocyte Count
MH  - *HIV Infections/drug therapy/immunology
MH  - Humans
MH  - Immune Reconstitution Inflammatory Syndrome/chemically induced/*diagnostic 
      imaging/*epidemiology
MH  - Incidence
MH  - Meningitis, Cryptococcal/drug therapy
MH  - Tuberculosis/drug therapy
MH  - Viral Load
PMC - PMC7162680
EDAT- 2020/04/01 06:00
MHDA- 2020/11/04 06:00
PMCR- 2020/01/01
CRDT- 2020/04/01 06:00
PHST- 2020/04/01 06:00 [entrez]
PHST- 2020/04/01 06:00 [pubmed]
PHST- 2020/11/04 06:00 [medline]
PHST- 2020/01/01 00:00 [pmc-release]
PST - ppublish
SO  - Top Antivir Med. 2020 Jan;27(4):106-111.